Purpose Cancer is one of the most common causes of death among young individuals. The purpose of this study was to explore the risk of early death (the first five years after diagnosis) among children (0-14 years), adolescents (15-19 years), and young adults (20-24 years) with cancer in Norway, born during 1965Norway, born during -1985 Methods The overall and cancer-specific early deaths were explored by linking population-based national registers (including the Cancer Registry of Norway and the Cause of Death Registry) that include the entire population of Norway (approximately 1.3 million individuals). Hazard and sub-hazard ratios were estimated using Cox regression analyses and competing risk models. Results A total of 5,828 individuals were diagnosed with cancer (56.3 % males). During follow-up, 1,415 individuals died from cancer (60.2 % males) within five years after diagnosis. The hazard ratio (HR) of overall death of the cancer patients relative to the general population decreased from 1965 (from HR, 385.8 (95 % confidence interval (CI): 335.3, 443.4) in 1965-74 to HR, 19.7 (CI: 9.3, 41.5) in 2005-09). Over all, there were fewer cancer-related deaths among female compared with male patients (sub-hazard ratio (SHR), 0.83 (CI: 0.74, 0.92)). Except for all hematopoietic malignancies, adolescents and young adult patients had lower risk of cancer death than children. Conclusion The difference in risk of cancer and overall deaths between the cancer patients and the general population has been substantially reduced since 1965. Keywords Childhood cancer Á Adolescents and young adults Á Early cancer death Á Norway Abbreviations ALL Acute lymphatic leukemia AML Acute myelogenic leukemia CI 95 % confidence interval CNS Central nervous system CRN Cancer Registry of Norway ICD-7 International Classification of Diseases-7 HR Hazard ratio SHR Sub-hazard ratio
Introduction
Although cancer is rare in childhood, adolescence, and early adulthood, it is one of the most common causes of death among young people in developed countries [1] [2] [3] [4] [5] [6] . How to handle cancer in young people is thus an important public health issue, both in terms of immediate and longterm consequences. Risk of death from cancer during early adulthood (20-24 years) is an under-studied phenomenon, as research on young people typically focuses on children (0-14 years) or adolescents (15-19 years) .
Over the past 30 years, the cancer mortality in young people has shown a substantial decline in developed countries [2, 7] , but less favorable in developing countries [8, 9] . In the USA, mortality from childhood cancer declined by 3.0 % per year for all neoplasms, and for childhood leukemia, the corresponding figure was 1.3 % [2] . In most European countries, childhood cancer mortality from all neoplasms has declined since 1960, with higher rates of death in Eastern Europe than in Western Europe and the USA [2, 4] . Similar results have also been reported for mortality of adolescents and young adults [10] . Furthermore, studies on adolescent and early adulthood cancer indicate a general reduction in mortality during recent decades [2, 4, 11] .
In 2008, 153 cases of cancer were diagnosed in Norway among children, and 56 and 94 new cancer cases were diagnosed among adolescents and young adults, respectively [11] . Today, due to improved medical treatments which include use of multimodal therapies, five-year survival of children less than 15 years is over 80 % [12] . In 2008, the cumulative risk of death caused by cancer among children, adolescents, and young adults were 0.05 % (0.03 %), 0.02 % (0.01 %) and 0.03 % (0.01 %) among males (females), respectively [11] .
The aim of this study was to explore the overall and cancer-specific death change during the past 40 years among children, adolescents, and young adults with cancer born in Norway during . Special attention was paid to tumors of the central nervous system (CNS), lymphomas, sarcomas, and leukemia, which are the most frequent cancer forms in these age-groups. The risk of early death predominantly reflects the efficacy of cancer treatment while the risk of late death most frequently is a sign of late effects of treatment. In this study, we were interested in the risk of early deaths and therefore, the follow-up time was restricted to the first 5 years after diagnosis.
Materials and methods

Data sources
Cancer Registry of Norway (CRN)
Since 1953, the CRN has received information on all cancer cases in the Norwegian population. Clinical notifications, pathological notifications, and death certificates are the main reporting sources and provide information about site, histological type, and stage of disease at the time of diagnosis [13] . Until 1992, registration of topography was based on a modified version of International Classification of Diseases-7 (ICD-7) [14] . From 1993 onwards, ICD-O-2 has been the basis for coding. Through 1992, tumor morphology was coded according to Manual of Tumor Nomenclature and Coding and since 1993, ICD-O morphology codes were adopted; separate systems have been used for non-solid tumors since 1986 [15] .
Cause of Death Registry, Norwegian Institute of Public Health
Since 1951, Norway has been obliged to prepare the official statistics on causes of death. The statistics cover persons registered as residents in Norway by the Central Population Register at the time of death, and whether the death took place in Norway or abroad. Statistics on causes of death are prepared on the basis of medical death certificates sent to Statistics Norway by public health officers. Underlying causes of death were coded according to the European short list for causes of death [16] .
Study cohort
All children born alive in Norway during 1965-1985, approximately 1.3 million individuals, were defined as our study cohort (644,358 males and 607,234 females). The individuals were followed up to adulthood until they were between 24 and 44 years of age. Furthermore, all children (0-14 years), adolescents (15-19 years) , and young adults (20-24 years) diagnosed with cancer were identified-a total of 5,828 individuals. These cancer patients were followed up until they were between 5 and 29 years of age (main analysis).
The cohort was followed from birth to adulthood by linking the Central Population Registry, the CRN, and the Cause of Death Registry, using the unique 11-digit identification number assigned to all individuals living in Norway after 1960.
Statistical analysis
A time-dependent Cox regression model with age as the time variable was applied to the entire cohort to estimate the risk of death (total death) among the cancer patients relative to the general population. Cancer was considered a time-dependent variable where the cancer status of the patients changed at the date of diagnosis. This model was adjusted for gender and year of birth (1965-1969, 1970-1974, 1975-1979, and 1980-1985) .
Among the cancer patients, a competing risk model [17] was used for the estimation of cancer death sub-hazard ratios (ratio of probabilities of a cancer-related death given that the patient has survived so far without any event of interest or any competing event), respectively, with time from diagnosis as the time variable. In the competing risk model, death from cancer was considered as the primary outcome, and deaths from non-cancer causes were considered a competing risk. Due to the low number of noncancer deaths, the risk of specific-non-cancer deaths within the first 5 years was not examined.
Although early mortality was the main focus of the current study, we also did some analysis on later deaths. However, due to the small number of deaths occurring more than 5 years after diagnosis, the results were not presented.
The proportionality assumption in the Cox model was evaluated by inspecting the log-minus-log plots.
The analysis of death among cancer patients diagnosed before the age of 25 was performed for all cancer sites combined and for the four most common cancer sites (CNS tumor (ICD-7; 193), bone and connective tissue (196-7), lymphatic system (206), and hematopoietic system (207)). Furthermore, acute lymphatic leukemia (ALL) and acute myelogenic leukemia (AML) were considered separately. We did not differentiate between Hodgkin and non-Hodgkin lymphoma since there were very few deaths among these patients, especially during 1965-1974 and 2005-2009 . The model included the variables gender, age at diagnosis (0-14, 15-19 and 20-24 years) , and year of diagnosis (1965-1974, 1975-1984, 1985-1994, 1995-2004, and 2005-2009 ). The age effect which was estimated in the main analysis was estimated across all periods of diagnosis and represented the net effect of age in the whole period. Comparison of agegroups in the same period of diagnosis could have been an informative supplement to our analysis since it does not assume that the age effect is similar across all periods of diagnosis. However, sub-analyses of age effects in each period of diagnosis were possible only for one period of diagnosis where all age categories were present (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) . We have performed analysis for this time period (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) and studied the age effect. In the main analysis, the cancer patients were followed up until 5 years after diagnosis, death, emigration, or December 31, 2009, whichever occurred first.
Death rates from cancer and other (non-cancer) causes were calculated by considering person-years at risk from the time of diagnosis. In Fig. 1 , patients below 1 year were presented separately since their death rate differed from the other age-groups.
The statistical packages PASW Statistics 18 (SPSS Inc. 2010, Chicago, IL) and Stata/IC 11 (StataCorp. 2010. Statistical Software: Release 11.0. College Station, TX: Stata corporation) were used to estimate the hazard ratios (HR) and sub-hazard ratios (SHR) with 95 percent confidence intervals (CI).
Ethics
The study was approved by the Regional Committee for Medical Research Ethics of Western Norway.
Results
A total of 5,828 individuals (3,281 males and 2,547 females; mean age, 14.7 years (range, 0-25 years)) were diagnosed with cancer and followed up (main analysis) for an average of 4.1 years (range, 0-5 years). Among these individuals, 1,506 deaths (94 % caused by cancer) were registered (Table 1) . Mean age at death among children was 6.4 years for males and 6.7 for females. Among adolescents and young adults, the mean ages were 17.8 and 22.7, respectively, for both genders.
Cancer occurrence
In each main diagnostic group, there were more males than females except for cancer of the thyroid gland and other endocrine glands, malignant melanoma and ''other,'' where 34.2, 26.5, and 47.9 % of the cases were males, respectively. Malignancies of the hematopoietic system and CNS tumors were most common in children. Among male patients older than 15 years, cancers of the testis, the lymphatic system, and CNS tumors were most frequent. In female adolescents and young adults, malignant melanomas, malignancies of the lymphatic system and CNS tumors, respectively, occurred most frequently. (Table 1) . In broad terms, the diagnostic gender differences were mirrored in the deaths, with a generally higher percentage of the deaths occurring among males, except for cancer of the kidney and malignant melanoma, constituting 45.9 and 44.4 % of the cases, respectively. During the past 40 years, there has been a substantial reduction in the death rates (Fig. 1) . The change in risk of cancer death rates varied by age and cancer site (Fig. 2) . The rates for some groups were based on limited numbers. The reduction in death from CNS tumors and all hematopoietic malignancies (also when ALL was considered separately) were highest among children, while death from cancer of the bone and connective tissue, the lymphatic system, and AML showed a substantial decline among the adolescents. The reduction in risk of death among young adults was moderate over the past 40 years.
Only 6 % of the deaths were due to non-cancer causes (91 cases), and 48 lacked a specified cause of death. However, a general reduction in early death from noncancer causes was observed for all age-groups (Fig. 1) . Among the 43 patients with specified cause of death, 12 (27.9 %) died from injury and poisoning, 4 (9.3 %) died from endocrine, nutritional and metabolic diseases, 4 (9.3 %) died from diseases of the blood and immunology disorders, 4 (9.3 %) died from diseases of the nervous system and the sense organs, 4 (9.3 %) died from diseases of the digestive system, 4 (9.3 %) from congenital malformations and chromosomal abnormalities, and 11 (25.6 %) died from other causes.
The entire study cohort (time-dependent Cox regression)
The hazard ratios (HR) of overall death for the entire study cohort (death among the cancer patients relative to the individuals without cancer) are presented in Table 2 . During the past four decades, a substantial decline in overall death among the cancer patients relative to the general population was observed. The HR of death among the cancer patients diagnosed during 1965-1974 was 385.8 (CI: 335.3, 443.9) which decreased to 19.7 (CI: 9.3, 41.5) during 2005-2009 relative to the general population. Death rates of the cancer patients relative to the general population within the first 5 years after diagnosis were considerably higher than those observed for the entire follow-up period (the total follow-up time of the cancer patients was on average 28.0 years (range, 0.1-45 years)).
The cancer patients (competing risk model)
Some cancer patients died from other causes than their cancer. In an attempt to measure only cancer-related deaths, we performed competing risk analyses; the results are summarized in Table 3 . Female cancer patients had a lower probability of cancer death compared with males, even when the other causes of deaths were taken into account. Furthermore, except for AML, a reduction in the Comparison of age-groups in the diagnosis period 1985-1994 showed similar trends as those presented earlier. Adolescents (SHR, 0.70 (CI: 0.60, 0.90)) and young adults (SHR, 0.44 (CI: 0.35, 0.56)) had lower risk of death than children.
Discussion
This population-based study showed a general decline in the risk of cancer death during the first 5 years after diagnosis for individuals diagnosed with cancer before the age of 25 during the last 40 years in Norway. Lower HRs of death for females than males were observed. Except for all hematopoietic malignancies (also when ALL was considered separately), adolescents and young adults had a lower HR of death compared with children.
Strengths and weaknesses
The strengths of this study were the cohort design, including all cancer cases (5,828 diagnosed before age 25) and all individuals in the country (1, 251, 592) , the linkage of comprehensive and compulsory registered databases with reliable information, and a minimal loss to follow-up (0.2 %). Reporting of cancer cases to the Cancer Registry of Norway has been compulsory since the 1950s, with a high degree of completeness [15] . The unique 11-digit identification number assigned at birth (or at immigration) to all individuals in Norway allows us to follow up the population over long time periods and to identify the cancer cases as well as the deaths.
The main weakness of this study was the lack of information on cancer treatment (chemotherapy, radiation therapy, or surgical procedures) at the individual level. However, the observed reduction in risk of cancer death reflects the improvements in general pediatric cancer care and implementation of effective chemotherapy regimens and tailored treatment protocols during the first two decades of the study period (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) , and despite a constant increase in health care costs, only a limited reduction of the death rates the last two decades of the study period . Another weakness of the study was the lack of information on cause-specific deaths from the Cause of Death Register before 1969. This study included 48 patients who died during 1965-1969, but for whom the cause of death was not specified. These cases were included as death from other causes in the analysis.
Comparison with the literature
In this study, the risk of cancer death among children, adolescents, and young adults in Norway was explored.
Overall changes in cancer death rates and gender differences were comparable to studies from Europe [1, 2, 4, 6, 7] , the USA [8, 18, 19] , and other developed countries [20] . Despite the improvements in developed countries over the recent decades, cancer in young age (0-24 years) continues to represent an important cause of death worldwide [4, 8, 21] . For instance, cancer was the second leading cause of death among children (defined as 1-14 years) in Australia from 2004 to 2006 and the fourth leading cause in Japan (defined as 0-14 years) [20, 22] . Studies show that decreases in cancer mortality rates are related to the improvements in treatments, including the adaption of effective and multidrug chemotherapy protocols worldwide [1, 2, 6, 8, 20, [23] [24] [25] .
Similar to other studies, CNS tumors, and malignancies of the hematopoietic and lymphatic system were the most common cancer sites [1, 24, 26, 27] . Studies from Europe have reported a substantial decline in mortality from childhood leukemia and other childhood cancers since the 1960s [2, 18] . These results were consistent with those of the current study. Unlike other studies with the largest reduction in mortality from leukemia and lymphoma [2, 8, (1965-1969, 1970-1974, 1975-1979, and 1980-1985) 18, 28] and a modest decline in death rates for pediatric brain tumors [18] and bone cancers [8] , we found a substantial decline in cancer death for the four major cancer sites (including ALL) and all cancers combined. The death rate from AML declined during 1975-1984 followed by a slight increase in 1985-1994. Since 1995, however, the death rate has decreased. Similar to the study by Gatta et al. [10] , a higher risk of death among adolescents than young adults was observed for all cancer sites combined (p \ 0.001). Some European studies on cancer among adolescents and young adults showed lower 5-year survival rates compared with children [4, 21, 27] . However, the results of the current study indicated, except for all hematopoietic malignancies (also when ALL was considered separately), generally higher death rates among children compared with adolescents and young adults. Adolescents with AML also had higher risk of death than children. This difference in results could be attributed to the choice of study population, age-grouping criteria, cancer sites, and/or the analytic methods.
The distribution of cancer types differs between children, adolescents, and young adults [12, 13] . While tumors with good prognosis like germ cell tumors, malignant melanoma, and Hodgkin lymphoma represent around onethird of the malignancies in adolescents and young adults; these cancers are infrequently observed in children. Non-Hodgkin lymphoma is more common than Hodgkin lymphoma among children, but adolescents and young adults are more likely to die from non-Hodgkin lymphoma compared with children [29] . The 5-year survival rates for ALL is worse for adolescents and young adults as compared with children [12], and the general impression is that adolescents and young adults do worse when they are diagnosed with pediatric cancers. In 2005, Hampton et al. [30] showed that adolescents and young adults were the age-group with the least improvements in 5 years survival of invasive cancer as compared with other age-groups. Thus, an explanation for the lower risk of death in adolescents and young adults as compared with children in our study might be the increased frequency of less aggressive cancers in this age-group (15-24 years) in the population.
The risk of early death, which was the main focus of this study, predominantly reflects the efficacy of cancer treatment, while risk of late death most frequently has become a sign of treatment-induced morbidity [31] . A recent study by Garwicz et al. [32] showed that the pattern of mortality was highly dependent on time since diagnosis. During the first few years after diagnosis, mortality was mainly due to the primary cancer; however, in longer follow-up time, mortalities were caused by second cancer and non-cancer causes. Due to improved therapy, 80 % of the children diagnosed with cancer will become long-term survivors [33] . Long-term survivors of childhood cancers are at increased risk of late mortality compared with the general population mainly due to treatment-related secondary neoplasms, and cardiac, and pulmonary deaths [31, [34] [35] [36] [37] . A Nordic study by Moller et al. [6] reported a reduction in the overall late mortality among long-term childhood cancer survivors over time. Furthermore, they indicated that modern therapies have reduced the late cancer mortality without increasing therapy-related death rates.
Excess mortality from second primary cancers and circulatory diseases continues to occur beyond 25 years after diagnosis [33, 37, 38] . Thus, a proportion of non-cancerrelated deaths in our study might have an association to cancer, and a longer observation time might have revealed additional cancer-related deaths. Also, there are discussions regarding the efficacy of treatment protocols, and there is a trend toward treating adolescents and young adults based on pediatric protocols. Ongoing studies are likely to provide answers to some of the questions raised in the near future.
Conclusion
This study provides trends in risk of early death among cancer patients diagnosed below the age of 25 in Norway. A general decline in risk of cancer death during the past four decades was observed. Furthermore, the differences in risk of death between the cancer patients and the general population have been substantially reduced since 1965.
